Neurofilaments: a key new biomarker for clinicians. Part 2: Neurofilaments, an asset beyond neurodegenerative diseases

IF 0.4 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Annales de biologie clinique Pub Date : 2022-09-01 DOI:10.1684/abc.2022.1758

Constance Delaby, Olivier Bousiges, Damien Bouvier, Catherine Fillée, Anthony Fourier, Étienne Mondésert, Nicolas Nezry, Souheil Omar, Isabelle Quadrio, Benoit Rucheton, Susanna Schraen-Maschke, Vincent van Pesch, Stéphanie Vicca, Sylvain Lehmann, Aurélie Bedel

{"title":"Neurofilaments: a key new biomarker for clinicians. Part 2: Neurofilaments, an asset beyond neurodegenerative diseases","authors":"Constance Delaby, Olivier Bousiges, Damien Bouvier, Catherine Fillée, Anthony Fourier, Étienne Mondésert, Nicolas Nezry, Souheil Omar, Isabelle Quadrio, Benoit Rucheton, Susanna Schraen-Maschke, Vincent van Pesch, Stéphanie Vicca, Sylvain Lehmann, Aurélie Bedel","doi":"10.1684/abc.2022.1758","DOIUrl":null,"url":null,"abstract":"<p><p>Neurofilaments (Nf) are proteins selectively expressed in the cytoskeleton of neurons, and their increase is a marker of neuronal damage. The potential utility of neurofilament light chain (NfL) has recently increased considerably, well beyond neurodegenerative diseases, due to analytical advances that allow measurement of their concentrations (even low ones) in cerebrospinal fluid and blood. This article completes the first part, in which we presented the interest of NfL in the context of neurodegenerative diseases. Here we focus our review on other clinical contexts of neurological injury (such as traumatic brain injury, multiple sclerosis, stroke, and cancer) and present the potential value of NfL assay in the management of these patients, for both diagnosis and prognosis. We also discuss the added value of the NfL assay compared to other biomarkers commonly used in the described clinical situations.</p>","PeriodicalId":7892,"journal":{"name":"Annales de biologie clinique","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales de biologie clinique","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1684/abc.2022.1758","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Neurofilaments (Nf) are proteins selectively expressed in the cytoskeleton of neurons, and their increase is a marker of neuronal damage. The potential utility of neurofilament light chain (NfL) has recently increased considerably, well beyond neurodegenerative diseases, due to analytical advances that allow measurement of their concentrations (even low ones) in cerebrospinal fluid and blood. This article completes the first part, in which we presented the interest of NfL in the context of neurodegenerative diseases. Here we focus our review on other clinical contexts of neurological injury (such as traumatic brain injury, multiple sclerosis, stroke, and cancer) and present the potential value of NfL assay in the management of these patients, for both diagnosis and prognosis. We also discuss the added value of the NfL assay compared to other biomarkers commonly used in the described clinical situations.

查看原文本刊更多论文

神经丝:临床医生重要的新生物标志物。第二部分:神经丝，超越神经退行性疾病的资产

神经丝(Nf)是神经元细胞骨架中选择性表达的蛋白质，其增加是神经元损伤的标志。由于分析技术的进步，可以测量脑脊液和血液中神经丝轻链(NfL)的浓度(即使是低浓度)，神经丝轻链(NfL)的潜在用途最近大大增加，远远超出了神经退行性疾病。本文完成了第一部分，其中我们介绍了NfL在神经退行性疾病背景下的兴趣。在这里，我们重点回顾了神经损伤的其他临床情况(如创伤性脑损伤、多发性硬化症、中风和癌症)，并介绍了NfL检测在这些患者的诊断和预后管理中的潜在价值。我们还讨论了与所描述的临床情况中常用的其他生物标志物相比，NfL测定的附加价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annales de biologie clinique 医学-医学：研究与实验

CiteScore

0.80

自引率

20.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Multidisciplinary information with direct relevance to everyday practice Annales de Biologie Clinique, the official journal of the French Society of Clinical Biology (SFBC), supports biologists in areas including continuing education, laboratory accreditation and technique validation. With original articles, abstracts and accounts of everyday practice, the journal provides details of advances in knowledge, techniques and equipment, as well as a forum for discussion open to the entire community.